Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Ultragenyx Pharma (RARE) PT Raised to $68 at Jefferies; Reiterates Hold
May 8, 2017 7:29 AM EDTJefferies raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $68.00 (from $66.00) while maintaining a Hold rating. 1Q expenses consisted of $51.3M R&D vs. $48.0M estimates, and $18.7M G&A vs. $20.2M.
Following recently reported ph.III KRN23 results in adult... More
